Entries by Jan Groen


View the most recent publications in which DGr Pharma is involved… Bradykinin Challenge Provides Surrogate Endpoints For Hereditary Angioedema TreatmentUsing Bradykinin-B2-Receptor Antagonists PHA-022121, a Selective Bradykinin-B2-Receptor Antagonist, Is Safe and Shows Rapid Oral Bioavailability in Humans


The DGr Pharma team is pleased to announce having obtained the endorsement of GLP compliance for the conduct of pharmacokinetic and toxicokinetic analyses after successfully passing a first GLP inspection by the Dutch GLP authority (IGJ). Please refer to the